Literature DB >> 35278095

[Stereotactic body radiotherapy as "first-line treatment" for oligometastatic renal cell cancer].

Matthias Guckenberger1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35278095     DOI： 10.1007/s00066-022-01920-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  3 in total

1.  Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy-A Radiobiological Sin-In Reply.

Authors:  David Palma; George Rodrigues; Richard Inculet
Journal:  JAMA Oncol       Date:  2019-09-01       Impact factor: 31.777

2.  Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.

Authors:  Brian I Rini; Thomas Powles
Journal:  N Engl J Med       Date:  2019-06-27       Impact factor: 91.245

3.  Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.

Authors:  Shankar Siva; Mathias Bressel; Simon T Wood; Mark G Shaw; Sherene Loi; Shahneen K Sandhu; Ben Tran; Arun A Azad; Jeremy H Lewin; Katharine E Cuff; Howard Y Liu; Daniel Moon; Jeremy Goad; Lih-Ming Wong; Michael LimJoon; Jennifer Mooi; Sarat Chander; Declan G Murphy; Nathan Lawrentschuk; David Pryor
Journal:  Eur Urol       Date:  2021-12-23       Impact factor: 24.267
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.